Condition

Stage III Adult T-cell Leukemia/Lymphoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions10

Lead sponsors shown3

Clinical trials

3 shown

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesNCT01273766 · 2011-01-01

COMPLETED

RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsNCT01158274 · 2010-06-01

COMPLETED

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerNCT00112593 · 1999-11-01

COMPLETED

Common interventions

laboratory biomarker analysisOTHER3 capecitabineDRUG1 cyclosporineDRUG1 deferasiroxDRUG1 enzyme-linked immunosorbent assayOTHER1 fludarabine phosphateDRUG1 gamma-secretase/Notch signalling pathway inhibitor RO4929097DRUG1 mycophenolate mofetilDRUG1 peripheral blood stem cell transplantationPROCEDURE1 total-body irradiationRADIATION1

Leading sponsors

Fred Hutchinson Cancer Center 1 National Cancer Institute (NCI) 1 Wake Forest University Health Sciences 1

Trial status mix

COMPLETED3

Phase mix

NA1

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.